Search

for
Search:

Research

5 / 389 results

research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

1 citations , July 2021 in “Frontiers in Oncology”

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

research Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq”

June 2026 in “Journal of cancer research updates”

Generic Palbociclib is safe and tolerable for treating certain breast cancer types.

Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study

research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.

June 2024 in “Journal of Clinical Oncology”

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

research Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm

4 citations , October 2018 in “Asia-Pacific Journal of Clinical Oncology”

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Optimizing Clinical Monitoring and Management Guidelines for Capivasertib in HR-Positive/HER2-Negative Advanced Breast Cancer: Expert Opinion

research Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion

December 2025 in “npj Breast Cancer”

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

View more "her2-negative" in research →

Learn

— no results

Try a deeper search in learn →

Community Join

— no results

Try a deeper search in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →